Modeling vaccination coverage during the 2022 central Ohio measles outbreak: a cross-sectional study.

Rosemary A Martoma, Matthew Washam, Joshua C Martoma, Anne Cori, Maimuna S Majumder
Author Information
  1. Rosemary A Martoma: Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States.
  2. Matthew Washam: Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States.
  3. Joshua C Martoma: KidsMates Inc., Boca Raton, FL, United States.
  4. Anne Cori: MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, United Kingdom.
  5. Maimuna S Majumder: Department of Pediatrics, Harvard Medical School, Boston, MA, United States.

Abstract

Background: Of the eight large (>50 cases) US postelimination outbreaks, the first and last occurred in Ohio. Ohio's vaccination registry is incomplete. Community-level immunity gaps threaten more than two decades of measles elimination in the US. We developed a statistical model, VaxEstim, to rapidly estimate the early-phase vaccination coverage and immunity gap in the exposed population during the 2022 Central Ohio outbreak.
Methods: We used reconstructed daily incidence (from publicly available data) and assumptions about the distribution of the serial interval, or the time between symptom onset in successive measles cases, to estimate the effective reproduction number (i.e., the average number of secondary infections caused by an infected individual in a partially immune population). We estimated early-phase measles vaccination coverage by comparing the effective reproduction number to the basic reproduction number (i.e., the average number of secondary infections caused by an infected individual in a fully susceptible population) while accounting for vaccine effectiveness. Finally, we estimated the early-phase immunity gap as the difference between the estimated critical vaccination threshold and vaccination coverage.
Findings: VaxEstim estimated the early-phase vaccination coverage as 53% (95% credible interval, 21%-77%), the critical vaccination threshold as 93%, and the immunity gap as 42% (95% credible interval, 18%-74%).
Interpretation: This study estimates a significant immunity gap in the exposed population during the early phase of the 2022 Central Ohio measles outbreak, suggesting a robust public health response is needed to identify the susceptible community and develop community-specific strategies to close the immunity gap.
Funding: This work was supported in part by the National Institute of General Medical Sciences, National Institutes of Health; the UK Medical Research Council (MRC); the Foreign, Commonwealth and Development Office; the National Institute for Health Research (NIHR) Health Protection Research Unit in Modelling Methodology; Imperial College London, and the London School of Hygiene & Tropical Medicine, Community Jameel; the EDCTP2 programme, supported by the EU; and the Sergei Brin Foundation.

Keywords

References

  1. Clin Infect Dis. 2011 Apr 1;52(7):911-6 [PMID: 21427399]
  2. Emerg Infect Dis. 2019 Jan;25(1):1-4 [PMID: 30560777]
  3. JAMA Pediatr. 2015 May;169(5):494-5 [PMID: 25774618]
  4. BMJ. 2017 May 16;357:j2378 [PMID: 28512183]
  5. PLoS Comput Biol. 2020 Dec 10;16(12):e1008409 [PMID: 33301457]
  6. Epidemics. 2019 Dec;29:100356 [PMID: 31624039]
  7. Clin Infect Dis. 2022 Aug 31;75(3):416-424 [PMID: 34849648]
  8. Pediatrics. 2021 Jan;147(1): [PMID: 33214332]
  9. JAMA Pediatr. 2014 Feb;168(2):148-55 [PMID: 24311021]
  10. Lancet. 2022 Feb 12;399(10325):678-690 [PMID: 35093206]
  11. J Theor Biol. 2011 Sep 7;284(1):52-60 [PMID: 21704640]
  12. Lancet Infect Dis. 2017 Dec;17(12):e420-e428 [PMID: 28757186]
  13. N Engl J Med. 2020 Mar 12;382(11):1009-1017 [PMID: 32160662]
  14. Pediatrics. 2014 Jul;134(1):e220-8 [PMID: 24913790]
  15. N Engl J Med. 2016 Oct 6;375(14):1343-1354 [PMID: 27705270]
  16. JAMA Pediatr. 2020 Jan 1;174(1):56-62 [PMID: 31738391]
  17. MMWR Morb Mortal Wkly Rep. 2019 May 17;68(19):444-445 [PMID: 31095533]
  18. PLOS Digit Health. 2022 Jun 27;1(6):e0000052 [PMID: 36812522]
  19. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S420-S428 [PMID: 34590128]
  20. JAMA. 2023 Jan 3;329(1):9-11 [PMID: 36520451]
  21. Pediatrics. 2011 Jul;128(1):79-85 [PMID: 21708796]
  22. Am J Epidemiol. 2013 Nov 1;178(9):1505-12 [PMID: 24043437]
  23. MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1563-1569 [PMID: 34758014]

Grants

  1. MR/R015600/1/Medical Research Council
  2. R35 GM146974/NIGMS NIH HHS

Word Cloud

Created with Highcharts 10.0.0vaccinationimmunitymeaslescoveragegapnumberOhioearly-phasepopulationestimatedMeasles2022outbreakintervalreproductionthresholdNationalHealthResearchcasesUSposteliminationeliminationVaxEstimestimateexposedCentraleffectiveieaveragesecondaryinfectionscausedinfectedindividualsusceptiblecritical95%crediblestudyresponsesupportedInstituteMedicalLondonBackground:eightlarge>50outbreaksfirstlastoccurredOhio'sregistryincompleteCommunity-levelgapsthreatentwodecadesdevelopedstatisticalmodelrapidlyMethods:usedreconstructeddailyincidencepubliclyavailabledataassumptionsdistributionserialtimesymptomonsetsuccessivepartiallyimmunecomparingbasicfullyaccountingvaccineeffectivenessFinallydifferenceFindings:53%21%-77%93%42%18%-74%Interpretation:estimatessignificantearlyphasesuggestingrobustpublichealthneededidentifycommunitydevelopcommunity-specificstrategiescloseFunding:workpartGeneralSciencesInstitutesUKCouncilMRCForeignCommonwealthDevelopmentOfficeNIHRProtectionUnitModellingMethodologyImperialCollegeSchoolHygiene&TropicalMedicineCommunityJameelEDCTP2programmeEUSergeiBrinFoundationModelingcentraloutbreak:cross-sectionalAntivaccinationmovementCriticalInfectiousdiseasecomplicationssurveillanceOutbreak-predictionmodelsRapidsystemsStatisticalmodellingUnitedStatesVaccinationVaccine-hesitancy

Similar Articles

Cited By